{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:20:42Z","timestamp":1770470442149,"version":"3.49.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>International guidelines recommend integrase strand-transfer inhibitor (INSTI)-based regimens as initial and switch therapy in people with HIV. As novel INSTIs become available, understanding how emergence of resistance at virological failures and seroconversions affects subsequent treatment options is needed. For the latest approved INSTI, cabotegravir, resistance patterns comprising Q148K\/R, N155H, R263K, G118R, E138A\/K and G140A\/S (alone or in combination) have been documented in virological failures and seroconversions. Here, the effect of these substitutions on antiviral activity of commercially approved INSTIs, bictegravir and elvitegravir, was assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Antiviral testing was performed using person-derived clinical isolates (n\u200a=\u200a52) with viral profiles similar to cabotegravir INSTI resistance patterns; susceptibility to cabotegravir, bictegravir and elvitegravir was measured using a phenotypic assay. Substitution patterns from isolates included triple [Q148K\/H\/R\u200a+\u200aE138A\/K\u200a+\u200aG140A\/C\/S (n\u200a=\u200a16)], double [Q148R\u200a+\u200aE138K (n\u200a=\u200a3); Q148H\/R\u200a+\u200aG140A\/S (n\u200a=\u200a24)] and single [N155H (n\u200a=\u200a6); Q148R (n\u200a=\u200a3)] resistance-associated mutations (RAMs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>IC50 fold changes (FCs) for triple RAMs were the highest, at 47.0, 7.59 and &amp;gt;144 for cabotegravir, bictegravir and elvitegravir, respectively. For cabotegravir, bictegravir and elvitegravir, respectively, mean IC50 FCs were 9.5, 2.5 and &amp;gt;144 for double RAMs; and 3.3, 1.4 and &amp;gt;65 for single RAMs. When considering clinical\/biological assay cut-offs, 54% (28\/52) of isolates were susceptible to bictegravir, 40% (21\/52) were partially susceptible and 6% (3\/52) were resistant; for elvitegravir, 100% of isolates were resistant. Cabotegravir cut-offs were not available at the time of reporting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Overall, clinical isolates with RAM patterns similar to clinically observed cabotegravir INSTI resistance showed meaningful increases in IC50 FCs, suggesting that cabotegravir-associated resistance may negatively affect efficacy of bictegravir- and elvitegravir-based regimens.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf019","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T06:39:26Z","timestamp":1737700766000},"page":"962-966","source":"Crossref","is-referenced-by-count":4,"title":["Assessing phenotypic effect of integrase strand-transfer inhibitor (INSTI)-based resistance substitutions associated with failures on cabotegravir"],"prefix":"10.1093","volume":"80","author":[{"given":"Michelle L","family":"D\u2019Antoni","sequence":"first","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , 333 Lakeside Drive, Foster City, CA 94404 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brie","family":"Falkard","sequence":"additional","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , 333 Lakeside Drive, Foster City, CA 94404 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Andreatta","sequence":"additional","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , 333 Lakeside Drive, Foster City, CA 94404 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Cox","sequence":"additional","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , 333 Lakeside Drive, Foster City, CA 94404 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cal","family":"Cohen","sequence":"additional","affiliation":[{"name":"Medical Affairs, Gilead Sciences, Inc. , 333 Lakeside Drive, Foster City, CA 94404 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , 333 Lakeside Drive, Foster City, CA 94404 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"2025040208375546400_dkaf019-B1","author":"Department of Health and Human Services (DHHS), Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2025040208375546400_dkaf019-B2","author":"European AIDS Clinical Society"},{"key":"2025040208375546400_dkaf019-B3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society\u2013USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2025040208375546400_dkaf019-B4","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2025040208375546400_dkaf019-B5","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2 M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"2025040208375546400_dkaf019-B6","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025040208375546400_dkaf019-B7","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"2025040208375546400_dkaf019-B8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2025040208375546400_dkaf019-B9","author":"Rana"},{"key":"2025040208375546400_dkaf019-B10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025040208375546400_dkaf019-B11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2025040208375546400_dkaf019-B12","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"key":"2025040208375546400_dkaf019-B13","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/infdis\/jiab576","article-title":"Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate\/emtricitabine for HIV prevention: HPTN 084","volume":"225","author":"Eshleman","year":"2022","journal-title":"J Infect Dis"},{"key":"2025040208375546400_dkaf019-B14","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"2025040208375546400_dkaf019-B15","author":"Gilead Sciences"},{"key":"2025040208375546400_dkaf019-B16","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208375546400_dkaf019-B17","author":"Gilead Sciences"},{"key":"2025040208375546400_dkaf019-B18","author":"WHO"},{"key":"2025040208375546400_dkaf019-B19","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1016\/S2352-3018(23)00228-X","article-title":"HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis","volume":"10","author":"Loosli","year":"2023","journal-title":"Lancet HIV"},{"key":"2025040208375546400_dkaf019-B20","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00365-4","article-title":"Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study","volume":"10","author":"Smith","year":"2023","journal-title":"Lancet HIV"},{"key":"2025040208375546400_dkaf019-B21","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1097\/QAD.0000000000003322","article-title":"Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis","volume":"36","author":"Ahluwalia","year":"2022","journal-title":"AIDS"},{"key":"2025040208375546400_dkaf019-B22","author":"ViiV Healthcare"},{"key":"2025040208375546400_dkaf019-B23","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.1038\/s41467-020-19801-x","article-title":"Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase","volume":"11","author":"Siedner","year":"2020","journal-title":"Nat Commun"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/962\/61615054\/dkaf019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/962\/61615054\/dkaf019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T09:16:28Z","timestamp":1743585388000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/4\/962\/7978118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,24]]},"published-print":{"date-parts":[[2025,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf019","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,1,24]]}}}